OCI Full Year 2024 Earnings: Misses Expectations

OCI (AMS:OCI) Full Year 2024 Results

Key Financial Results

• Revenue: US$975.1m (down 50% from FY 2023).
• Net loss: US$382.2m (loss narrowed by 51% from FY 2023).
• US$1.81 loss per share (improved from US$3.71 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

OCI Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 51%. Earnings per share (EPS) was also behind analyst expectations.

The primary driver behind last 12 months revenue was the Nitrogen EU segment contributing a total revenue of US$976.5m (100% of total revenue). Notably, cost of sales worth US$973.1m amounted to 100% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$231.9m (60% of total expenses). Explore how OCI's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe.

Performance of the market in the Netherlands.

The company's shares are down 1.9% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with OCI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.